Abstract
Alefacept has demonstrated efficacy for patients with chronic plaque psoriasis and it offers the potential to maintain their response for prolonged periods of 7 months or more without the need for continuous therapy. Longer term clinical use continues to support the favorable safety profile of this biologic agent. The future of alefacept may include use in other forms of psoriasis, including psoriatic arthritis, palmoplantar psoriasis and nail psoriasis, use in combination with other therapies, such as ultraviolet light and systemic retinoids and alternative dosage strategies to improve response.
Conflict of interest
Charles Lynde is a clinical investigator, speaker and/or consultant for the following companies: Astellas Pharma Inc., Biogen Idec, Serono, Genentech, Centocor, and Amgen/Wyeth Pharmaceuticals. Paula Dakin is a former employee of Biogen Idec.